Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Abbott's Receives FDA Approval For Esprit BTK Everolimus Eluting Resorbable Scaffold System

Author: Benzinga Newsdesk | April 29, 2024 09:03am
  • More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options
  • The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK)
  • The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD

 

Posted In: ABT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist